Wang Zi-Fa, Zhu Zhi-Jun, Shen Zhong-Yang
Oriental Organ Transplantation Center, Tianjin First Central Hospital, Tianjin 300191, China.
Hepatobiliary Pancreat Dis Int. 2005 Nov;4(4):509-14.
In the 1990s, liver transplantation for hepatitis B virus (HBV) related-liver diseases was a very controversial issue because the graft was inevitably recurrent after liver transplantation. Significant progress has been made in the prophylaxis and treatment of recurrent hepatitis B after liver transplantation. This review covers the mechanisms, prophylaxis, and treatment of hepatitis B recurrent after liver transplantation.
Searching MEDLINE (1995-2004) for articles on liver transplantation.
HBV reinfection after liver transplantation results from HBV particles in circulation or other extrahepatic sites. Hepatitis B immune globulin (HBIG) was effective in reducing HBV reinfection and improving graft survival after liver transplantation. Lamivudine has also dramatically reduced the recurrence of HBV in the patient undergoing liver transplantation.
Combination HBIG and lamivudine is the most effective porphylatic regimen. Lamivudine and adefovir are highly effective in treatment of HBV recurrence. HBV-related liver disease is no longer a contraindication for liver transplantation.
在20世纪90年代，乙肝病毒（HBV）相关肝病的肝移植是一个极具争议的问题，因为肝移植后移植物不可避免地会复发。肝移植后复发性乙型肝炎的预防和治疗已取得重大进展。本综述涵盖肝移植后乙型肝炎复发的机制、预防和治疗。
检索MEDLINE（1995 - 2004年）中关于肝移植的文章。
肝移植后HBV再感染源于循环中的HBV颗粒或其他肝外部位。乙肝免疫球蛋白（HBIG）在降低肝移植后HBV再感染及提高移植物存活率方面有效。拉米夫定也显著降低了肝移植患者HBV的复发率。
HBIG与拉米夫定联合是最有效的预防方案。拉米夫定和阿德福韦酯在治疗HBV复发方面非常有效。HBV相关肝病不再是肝移植的禁忌证。
Zotero 插件